«Previous Article|Table of Contents|Next Article»

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:

2024 01

Page:

1-7

Research Field:

Publishing date:

Info

Title:

The expression of lncRNA CTD-2182N23.1 in papillary thyroid carcinoma tissues and its influence on the malignant biological behavior of papillary thyroid carcinoma cells

Author(s):

LI Siyi¹; XIAO Xiongsheng¹; CHEN Zhuoting¹; YANG Xue²; ZHENG Changwei¹; ZHANG Zhi¹

1.Department of Vascular and Thyroid Surgery,Affiliated Hospital of Guangdong Medical University,Guangdong Zhanjiang 524000,China;2.Department of Oncology,Affiliated Hospital of Qingdao University,Shandong Qingdao 266003,China.

Keywords:

long non-coding RNA; papillary thyroid carcinoma; miR-200c-3p; ATP2A2; proliferation; invasion

PACS:

R736.1

DOI:

10.3969/j.issn.1672-4992.2024.01.001

Abstract:

Objective:To analyze the relationship between the expression level of long non-coding RNA(lncRNA) CTD-2182N23.1 in papillary thyroid carcinoma tissues and the clinicopathological characteristics of patients.To explore the effect of CTD-2182N23.1 on the malignant biological behavior of papillary thyroid carcinoma cells by targeting miR-200c-3p.Methods:The TCGA database was used to analyze the expression of CTD-2182N23.1 in papillary thyroid carcinoma tissues and its relationship with the clinical stage and prognosis of patients.From May 2019 to March 2022,the cancer tissues and paracancerous tissues of 50 patients with papillary thyroid carcinoma who underwent surgical resection in our hospital were collected,and real-time quantitative polymerase chain reaction(qPCR) was used to detect the expression of CTD-2182N23.1 in papillary thyroid carcinoma tissues.The relationship between its expression and the clinicopathological features of patients with papillary thyroid carcinoma was analyzed.The expression of CTD-2182N23.1 in human normal thyroid follicular epithelial cells Nthy-ori3-1 and human papillary thyroid carcinoma cell lines TPC-1,MDA-T32,TT,SW579,and B-CPAP was detected by qPCR.MDA-T32 cells were cultured in vitro and divided into NC group and CTD-2182N23.1 group.Cell clone formation assay and Transwell assay were used to detect the proliferation and invasion abilities of transfected MDA-T32 cells,respectively.The dual luciferase gene reporter assay verified the targeting relationship between CTD-2182N23.1 and miR-200c-3p.The expression of miR-200c-3p and ATP2A2 mRNA in MDA-T32 cells after transfection was detected by qPCR.The correlation between CTD-2182N23.1 and ATP2A2 mRNA expression was analyzed using TCGA database.The protein levels of ATP2A2,CDK1,Cyclin B,Twist and Slug were detected by Western blot respectively.Results:The TCGA database showed that the expression of CTD-2182N23.1 in papillary thyroid carcinoma tissues was low(P＜0.01),which was positively correlated with the clinical stage and disease-free survival of patients(all P＜0.05).qPCR results showed that CTD-2182N23.1 was lowly expressed in papillary thyroid carcinoma tissues and cell lines(all P＜0.05).The expression level of CTD-2182N23.1 was correlated with tumor stage and lymph node metastasis(all P＜0.01).After up-regulation of CTD-2182N23.1,the number of MDA-T32 cell colony formation and the number of cell invasion were significantly reduced(all P＜0.01).CTD-2182N23.1 can target and negatively regulate the expression of miR-200c-3p(P＜0.01).The expression of ATP2A2 gene in MDA-T32 cells was significantly increased after up-regulation of CTD-2182N23.1(P＜0.01).CTD-2182N23.1 was positively correlated with ATP2A2 mRNA expression.After up-regulating CTD-2182N23.1,the protein levels of CDK1,Cyclin B,Twist,and Slug in MDA-T32 cells were significantly decreased(all P＜0.01).Conclusion:CTD-2182N23.1 is low expressed in papillary thyroid carcinoma tissues and cell lines,and up-regulation of CTD-2182N23.1 can significantly inhibit the proliferation and invasion of papillary thyroid carcinoma cells by regulating the expression of miR-200c-3p/ATP2A2.CTD-2182N23.1 may be a potential molecular target for papillary thyroid carcinoma therapy.

References:

[1]CHOU R,DANA T,HAYMART M,et al.Active surveillance versus thyroid surgery for differentiated papillary thyroid carcinoma:A systematic review ［J］.Thyroid,2022,32(4):351-367.
[2] MANIAKAS A,ZAFEREO M,CABANILLAS ME.Anaplastic thyroid cancer:New horizons and challenges ［J］.Endocrinol Metab Clin North Am,2022,51(2):391-401.
[3] DAVID C SHONKA JR,ALAN HO,ASHISH V CHINTAKUNTLAWAR,et al.American head and neck society endocrine surgery section and international thyroid oncology group consensus statement on mutational testing in papillary thyroid carcinoma:defining advanced papillary thyroid carcinoma and its targeted treatment ［J］.Head Neck,2022,44(6):1277-1300.
[4] ROSELAND ME,DEWARAJA YK,WONG KK.Advanced imaging and theranostics in papillary thyroid carcinoma ［J］.Curr Opin Endocrinol Diabetes Obes,2022,29(5):456-465.
[5] ZENG H,HOU Y,ZHOU X,et al.Cancer-associated fibroblasts facilitate premetastatic niche formation through lncRNA SNHG5-mediated angiogenesis and vascular permeability in breast cancer ［J］.Theranostics,2022,12(17):7351-7370.
[6] LI Z,WANG H,DENG X,et al.Construction and validation of an immune-related lncRNA prognosis model for papillary thyroid carcinoma ［J］.Comb Chem High Throughput Screen,2022,25(13):2217-2227.
[7] LIU Y,SHI P,FANG H,et al.Long non-coding RNA GHET1 promotes papillary thyroid carcinoma cell proliferation and invasion ［J］.Transl Cancer Res,2021,10(9):4148-4157.
[8] HAN T,LIAO A.CASC7:a lncRNA with potential clinical application ［J］.Int J Radiat Biol,2022,98(10):1510-1518.
[9] ZHANG N,ZHANG H,WU W,et al.Machine learning-based identification of tumor-infiltrating immune cell-associated lncRNAs for improving outcomes and immunotherapy responses in patients with low-grade glioma ［J］.Theranostics,2022,12(13):5931-5948.
[10] SHAN Y,HE R,YANG X,et al.An autophagy-related lncRNA prognostic risk model for papillary thyroid carcinoma ［J］.Eur Arch Otorhinolaryngol,2022,279(3):1621-1631.
[11] LI Z,YUE G,LI M,et al.LncRNA GAS8-AS1 is a novel prognostic and diagnostic biomarker for pancreatic cancer ［J］.Crit Rev Eukaryot Gene Expr,2022,32(4):83-92.
[12] TAN F,CHEN J,WANG B,et al.LncRNA SBF2-AS1:a budding star in various cancers ［J］.Curr Pharm Des,2022,28(18):1513-1522.
[13] ZHU Y,JIN L,SHI R,et al.The long noncoding RNA glycoLINC assembles a lower glycolytic metabolon to promote glycolysis ［J］.Mol Cell,2022,82(3):542-554,e546.
[14] 彭学姣，许天敏，常伟勤.长链非编码RNA在甲状腺乳头状癌中的研究进展［J］.现代肿瘤医学2018,26(23):3872-3875. PENG XJ,XU TM,CHANG WQ.Research progress of long noncoding RNA in diagnosis and treatment of papillary thyroid cancer Modern Oncology,2018,26(23):3872－3875.
[15] LU H,ZHU C,CHEN Y,et al.LncRNA ABHD11-AS1 promotes tumor progression in papillary thyroid carcinoma by regulating EPS15L1/EGFR signaling pathway ［J］.Clin Transl Oncol,2022,24(6):1124-1133.
[16] QI F,TANG J,CAI Z,et al.Long non-coding RNA CATIP antisense RNA 1(lncRNA CATIP-AS1) downregulation contributes to the progression and metastasis of papillary thyroid carcinoma via epithelial-mesenchymal transition(EMT) pathway ［J］.Bioengineered,2022,13(3):7592-7606.
[17] TIAN F,YING H,LIAO S,et al.lncRNA SNHG14 promotes the proliferation,migration,and invasion of thyroid tumour cells by regulating miR-93-5p ［J］.Zygote,2022,30(2):183-193.
[18] MA H,SHI Q,FANG J,et al.Long non-coding RNA AFAP1-AS1 promotes papillary thyroid carcinoma progression by sponging miR-204-3p and upregulating DUSP4 ［J］.J Biochem,2022,171(1):131-140.
[19] JIA H,SUN W,LI X,et al.Melatonin promotes apoptosis of papillary thyroid carcinoma cells via regulating the signaling of microRNA-21(miR-21) and microRNA-30e(miR-30e) ［J］.Bioengineered,2022,13(4):9588-9601.
[20] LAN H.Regulatory effects of lncrNA SNHG4 on miR-25/FBXW7 axis in papillary papillary thyroid carcinoma cells ［J］.Crit Rev Eukaryot Gene Expr,2022,32(7):1-9.
[21] ZHANG C,HUA Y,ZHONG X.LncRNA UCA1 promotes tumorigenesis of breast cancer via targeting miR-185-5p ［J］.Minerva Med,2022,113(5):889-890.
[22] NAVARRO-MANZANO E,LUENGO-GIL G,GONZALEZ-CONEJERO R,et al.Prognostic and predictive effects of tumor and plasma miR-200c-3p in locally advanced and metastatic breast cancer ［J］.Cancers(Basel),2022,14(10):2390.
[23] PAN Y,SHAO S,SUN H,et al.Bile-derived exosome noncoding RNAs as potential diagnostic and prognostic biomarkers for cholangiocarcinoma ［J］.Front Oncol,2022,24:985089.
[24] FENG YL,KE T,WANG GL,et al.MicroRNA-200c-3p negatively regulates ATP2A2 and promotes the progression of papillary thyroid carcinoma ［J］.Biochem Genet,2022,60(5):1676-1694.

Memo

Memo:

National Natural Science Foundation of China（No.81801734）;国家自然科学基金（编号：81801734）

Common functions

Last Update: 2023-11-30